Supplemental material
Journal of Medical Economics
Volume 27, 2024 - Issue 1
Oncology
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
Martijn J. H. G. Simonsa Evidence & Access, OPEN Health, Rotterdam, The Netherlands
https://orcid.org/0000-0001-5248-1676
https://orcid.org/0000-0001-5248-1676, Peter M. Machielsenb Exact Sciences, Baar, SwitzerlandCorrespondence[email protected]
https://orcid.org/0000-0002-8056-8063
https://orcid.org/0000-0002-8056-8063, Jelle A. Spoorendonka Evidence & Access, OPEN Health, Rotterdam, The Netherlandshttps://orcid.org/0000-0003-3687-4968
https://orcid.org/0000-0003-3687-4968, , , & Felix E. de Jonghc Ikazia Ziekenhuis Rotterdam, Rotterdam, The Netherlandshttps://orcid.org/0000-0002-1925-6263
https://orcid.org/0000-0002-1925-6263 show all